|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7977488||PHATHOM||1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors|| |
(4 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9186411||PHATHOM||Pharmaceutical composition|| |
(6 years from now)
Voquezna Triple Pak is owned by Phathom.
Voquezna Triple Pak contains Amoxicillin; Clarithromycin; Vonoprazan Fumarate.
Voquezna Triple Pak has a total of 2 drug patents out of which 0 drug patents have expired.
Voquezna Triple Pak was authorised for market use on 03 May, 2022.
Voquezna Triple Pak is available in capsule, tablet, tablet;oral dosage forms.
Drug patent challenges can be filed against Voquezna Triple Pak from 2031-05-04.
The generics of Voquezna Triple Pak are possible to be released after 03 May, 2032.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||May 3, 2027|
|Generating Antibiotic Incentives Now (GAIN)||May 3, 2032|
NCE-1 date: 2031-05-04
Market Authorisation Date: 03 May, 2022
Dosage: CAPSULE, TABLET, TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic